Evaluation Report on European HIV Testing Week 2014 Activities


The Evaluation report on European HIV Testing Week 2014 has been published. It includes a full evaluation on activities implemented all across Europe. The report was prepared by HIV in Europe, who is the motivator behind this pan-European initiative.

The report includes data on participating organisations, data on testing uptake, target groups outreached and tested, media coverage of the ETW. The report also includes examples of ‘best practices’ from the European Testing Week, and among these ‘best practices’ is the successful action implemented by Q-Club in cooperation with Association Duga, Belgrade institute for public health and Institute for public health of Serbia„Dr Milan Jovanović Batut“, but also the successful regional action implemented by NeLP (Network of low HIV prevalence countries in Central and South East Europe).

You can see the full testing week 2014 evaluation report here.


Set of recommended measurements for achieving equality


Commissioner for Equality gave a Set of recommended measurements for achieving equality, intended for the Ministry of Health of Republic of Serbia. These recommended measures encompasses all healthcare institutions under jurisdiction of the Ministry of Health and are about the procedure of inscribing patients’ HIV status on healthcare documents in these institutions.

This set of recommended measures is a result of researches and documented cases of discriminations where the HIV status of the patient was additionally, but irregularly, stressed and overmarked on healthcare documents. This contributes to stigmatisation of PLHIV, who are already ostracised and marginalised by the society.

You can read the set of recommendations in Serbian here



Negotiation Chapter 28 – Meeting in the Serbia Palace


Meeting of representatives of the civil society organisations interested in the negotiation process of accession to the European Union within the section 28 and the government accession negotiation team took place in the Serbia Palace on March 2nd 2015 and was organised by the Office for cooperation with the civil society. Chapter28 pertains to consumer and health protection.

The meeting was opened by Ivana Ćirković – head of the Office for cooperation with the civil society, Vesna Kovač – state secretary in the Ministry of commerce, toursim and telecommunications and coordinatior of negotiations peratining to chapter 28, and Predrag Sazdanović – Assistant of the Minister of Health. Most attention of the participants was attracted by the speach by Mr. Sazdanović, and most of the questions were driected at him, but the Assistant Minister did not have to answer all of them completely.

In the second half of the meeting, Mr. Dalobor Matić from the Ministy of external affairs of Croatia presented experiences fro his country in the negotiation process and the challenges they faced within this chapter, primarily in the domain of consumer protection. The negotiation process is very significant and presents a good opportunity to improve the healthcare system with the support and constructive participation from the civil society. However, with all praises to the Office to organize this meeting, there is a feeling that representative of the government should be more open to suggestions and problems of the civil society in order to achieve good progress and expected social reforms.

Representing Q-Club on this meeting was Nenad Petković.


Meeting of the Republic Healthcare Fund and Patient Organisations


The new director of the Republic Healthcare fund has invited members of the Patient Organisations in Serbia to a meeting which took place in the offices of the Healthcare Fund on February 26 2015. The goal of this meeting was mutual introduction as well as initial presentation of problems that patient organizations have. There were more than 30 representatives of various organizations, and representing the Healthcare Fund, along with the director were Sanja Mirosavljević and Aleksandra Gazivoda – both of them working on cooperation with patients.

In her introduction speech, the director, Ms Lazić stressed that her commitment was to improve relations and cooperation with patient organizations, which was well received by patient groups representatives. The general conclusion was that this direct cooperation between the Fund and patient groups was a good initiative. However, for further improvements thematic meetings would be needed – such meetings would gather representatives of patient organizations with similar problems, and they would be an opportunity to consider specific problems. The Republic Healthcare Fund took upon itself to schedule these meetings in the forthcoming period.

Representing Q-Club on this meeting was Nenad Petković.


The HIV Prevention Manifesto: we need PrEP now!


Open letter from HIV & LGBT European community organisations and other concerned Europeans to pharmaceutical industries, European and national institutions.


In recent years, there has been considerable debate about the role that antiretroviral drugs (ARVs) could play in combined HIV prevention strategies. One way of using them is as pre-exposure prophylaxis (PrEP); this involves the use of specific ARVs to reduce the risk of infection in HIV-negative people who are exposed to HIV. In 2012, the US Food and Drug Administration (FDA) announced its approval of daily oral tenofovir and emtricitabine (Truvada(R)) for PrEP. In Europe, this combination is not available for prevention except to people enrolled in scientific studies.

Recently, two major European scientific studies, the English PROUD trial and the French IPERGAY trial, reported the highest effectiveness rates yet seen in studies of pre-exposure prophylaxis (PrEP) for HIV.

These results are ground-breaking. A European licence for a measure that was approved by the US Food and Drug Administration in 2012, and which is already being used by at least 12,500 people in the US, is overdue.

Some of the questions raised by a possible licensed use of ARVs for PrEP in Europe are complex. How will people be assessed for PrEP? Where and how will it be delivered? Who will pay for it? How do we align it with the specific situations of different affected communities? None of these issues are unmanageable and, given the additional opportunity for HIV prevention and sexual health that PrEP is opening up, questions around its implementation and impact deserve an open discussion between communities affected by the HIV epidemic, health professionals, policy-makers and the companies producing the ARVs used for PrEP. Meanwhile, steps must be taken to make PrEP available.

This call from HIV and LGTB community organisations in Europe to both public health authorities and pharmaceutical companies is released as part of efforts to improve HIV prevention, sexual health and health seeking behaviour among gay men and other men having sex with men who are at risk of HIV infection.

As European community-based organisations we publicly raise the following points:

  • The number of new HIV infections in Europe continues to increase, particularly among key populations (men who have sex with men, people in prison, people who inject drugs, sex workers, transgender people and migrants among others).
  • We need to improve the HIV prevention tools and strategies for the key populations at increased risk for HIV acquisition.
  • We need to have additional prevention tools and to develop strategies combining them. This is the only way to end the HIV pandemic.
  • The effectiveness of PrEP has been proven in high-quality randomised studies, in Europe; they show that PrEP dramatically reduces the risk of HIV transmission.
  • PrEP is needed in Europe now and we are demanding it. The PROUD and IPERGAY studies and other community-based research show that there is demand for PrEP from people at high risk for HIV.
  • There already exists some informal use of PrEP. This informal use lacks adequate medical follow-up. Key populations need to choose if they want to use PrEP, and do it safely

We call on all stakeholders to make PrEP available and accessible in Europe:

  • We ask that Gilead, the manufacturers of Truvada®, to immediately file for a PrEP indication for Truvada® to the European Medicines Agency (EMA). We ask the EMA to clarify the regulatory pathway for access to PrEP.
  • We ask that pharmaceutical companies work with independent researchers to conduct implementation research on PrEP as part of programmes to make it available. PrEP must be effective, safe and easy to use.
  • We ask the European Centre for Disease Control and Prevention (ECDC) to initiate a working group on European PrEP guidelines. This group should include civil society and clinical organisations. These guidelines should:
    • Help define when PrEP provides most benefit;
    • Address access across Europe;
    • Define a follow-up protocol for people taking PrEP.
  • We ask European governments to examine ways to make PrEP reimbursable for those who need it.
  • We demand that PrEP is integrated into a wider and holistic sexual health strategy, which should also include counselling, testing, treatment and vaccination for STIs, condom and lubricant provision, post-exposure prophylaxis and self-support groups. No single prevention method should set in competition with others.

The successful implementation of combination HIV prevention needs evidence and evidence-based strategies and scientific and civil society organisations need to work together to provide them. Key populations need up-to-date information on new choices in order to take the best decisions to improve the quality of their health, happiness and social efficacy.

Q-Club is one of the signatories of this initaitve. You can see the manifesto here.


Five year report